E-Mail
Health Level Seven International (HL7®) and the Observational Health Data Sciences and Informatics (OHDSI) network announced a collaboration to address the sharing and tracking of data in the healthcare and research industries by creating a single common data model. The organizations will integrate HL7 Fast Healthcare Interoperability Resources (FHIR®) and OHDSI s Observational Medical Outcomes Partnership (OMOP) common data model to achieve this goal.
HL7 International CEO Dr. Charles Jaffe, M.D., Ph.D., underscored the significance of this partnership. The Covid-19 pandemic has emphasized the need to share global health and research data. He continued, Collaboration with OHDSI is critical to solving this challenge and will help our mutual vision of a world in which everyone can securely access and use the right data when and where they need it.
Patients on ACE inhibitors, ARBs, don t have higher COVID-19 risk medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
E-Mail
NEW YORK, NY (Dec. 17, 2020) While the COVID-19 pandemic left the world searching for answers during the earliest stages of the pandemic, one immediate healthcare concern regarded the use of certain antihypertensives and whether they posed increased risks to patients with hypertension.
A new study by global collaborators within the Observational Health Data Sciences and Informatics (OHDSI) community found that there was no increased risk of COVID-19 diagnosis, hospitalization, or subsequent complications for users of either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) among an international cohort of more than 1.1 million patients using antihypertensives.
The study was published today in
Antihypertensives Don t Raise the Risk of Contracting COVID-19 by Angela Mohan on December 18, 2020 at 11:49 AM
Antihypertensives like ACE inhibitors or ARBs doesn t increase the risk of COVID-19, according to study on more than 1.1 million patients.
The new study by global collaborators within the Observational Health Data Sciences and Informatics (OHDSI) community found that there was no increased risk of COVID-19 diagnosis, hospitalization, or subsequent complications.
This real-world evidence, generated through open-science approaches, support recent regulatory and clinical recommendations that patients should not discontinue ACE inhibitor or ARB therapy due to concerns of increased COVID-19 risk. People with hypertension have worse COVID-19 outcomes, and there remains speculation that some anti-hypertensive medications may be detrimental, says corresponding author Marc A. Suchard, a professor at UCLA and research team leader. The clear answer is th